Health Canada Recalls One PMS-FAMPRIDINE Lot Over Possible Foreign Particles

Health Canada has posted a retailer-level, Type II recall for one lot of PMS-FAMPRIDINE 10 mg tablets after a warning that it may contain foreign material particles. The affected product is made by Pharmascience Inc.; the notice identifies DIN 02496216 and lot 24123884. The alert was published September 28, 2026.

The listed distribution covers Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Ontario and Quebec. This is a lot-specific recall, not a notice that every package of PMS-FAMPRIDINE is affected. Health Canada does not describe the particles, confirm patient injuries or give a root cause in its public notice.

What pharmacy teams can do

• Check the DIN, strength and lot number on stock and patient packages against the federal notice before treating a package as affected.
• Follow the distributor or manufacturer’s recall instructions for any affected inventory, and document the stock check and disposition under local procedures.
• When a patient calls, verify the package rather than relying on the drug name alone. Health Canada advises patients to consult a healthcare provider before discontinuing the product or for any health concern.
• Escalate a possible interruption of therapy for an individualized clinical plan; the recall notice does not provide a universal substitution instruction.
• Direct product questions to Pharmascience and report suspected adverse effects or other product-safety complaints through Health Canada’s reporting routes.

The precise product identifiers matter more than a photograph: the accompanying image shows unidentified tablets and does not depict the recalled medicine. Pharmacies should use the package label and the linked federal notice as the source of truth.